Great progress has been made in recent years to reduce the high level of suffering caused
by malaria worldwide. Notably, the use of insecticide-treated mosquito nets for malaria …

The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories.
The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process …

Diverse compounds target the Plasmodium falciparum Na+ pump PfATP4, with cipargamin
and (+)-SJ733 the most clinically-advanced. In a recent clinical trial for cipargamin …

Despite decades of research, little is known about the cellular targets and the mode of action
of the vast majority of antimalarial drugs. We recently demonstrated that the cellular thermal …

Preventing human-to-mosquito transmission of malaria parasites provides possible
solutions to interrupt the malaria parasite life cycle for malaria elimination. The development …

We identify the Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS) as a
druggable target, using genetic and chemical validation. In vitro evolution of resistance with …

Plasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that
cause the majority of cases of human malaria, have developed resistance to nearly all …

In vitro evolution of drug resistance is a powerful approach for identifying antimalarial
targets, however, key obstacles to eliciting resistance are the parasite inoculum size and …

INTRODUCTION Malaria remains a devastating disease, affecting 216 million people
annually, with 445,000 deaths occurring primarily in children under 5 years old. Malaria …

Infections caused by malaria parasites place an enormous burden on the world's poorest
communities. Breakthrough drugs with novel mechanisms of action are urgently needed. As …